Document is current
Any future updates will be listed below
-
Authors
Schmidt, Marc T.
Studer, Marc
Kunz, Andres
Studer, Sandro
Bonvini, John M.
Bueter, Marco
Kook, Lucas
Haile, Sarah R.
Pregernig, Andreas
Beck-Schimmer, Beatrice
Schläpfer, Martin
- License Information
-
More Information
Article History
Received: 6 April 2022
Accepted: 9 January 2023
First Online: 6 February 2023
Declarations
:
: This study was approved by the local ethics committee (Kantonale Ethikkommission Zurich, Zurich, Switzerland, number 2017 – 01790) as well as by the national authorization and supervisory authority for drugs and medical products (Swissmedic Bern, Switzerland, notification number 2017DR2183). All patients provided written and informed consent before the study intervention. All study interventions were conducted following the national and international guidelines and in accordance with the Declaration of Helsinki.
: Not applicable.
: Sandro Studer, Andres Kunz, Marc Schmidt, Sarah Haile, Lucas Kook, Andreas Pregernig, and Marco Bueter declare no conflicts of interest.Beatrice Beck-Schimmer: BBS received a grant from Baxter AG (not related to this work). BBS was a participant in an Advisory Board Meeting of Baxter AG (not related to this topic). BBS has a patent 04/10/14 – 20140100278: Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia–reperfusion event; M. Urner, L.K. Limbach, I.K. Herrmann, W.J. Stark, B. Beck Schimmer, applied as Patent Cooperation Treaty (PCT) (internationally), July 2009, as well as a patent application on bioconjugates of antibodies and functionalized magnetic nanoparticles. BBS and Martin Schläpfer have received Sedana Medical AB, Danderyd, Sweden, grant money as collaborators of a large multicenter study ‘Inhaled Sedation in COVID-19-related acute respiratory distress syndrome (ISCA): an international research data study in the recent context of widespread disease resulting from the 2019 (SARS-CoV2) coronavirus pandemics (COVID-19), not related to this topic.Martin Schläpfer has received research money for an investigator-initiated trial from Roche AG, Switzerland, not related to this study, and travel support from Baxter AG, Switzerland, as well as research money from Sedana Medical AB, Danderyd, Sweden, for another investigator-initiated trial, not related to this study. Martin Schläpfer, Beatrice Beck-Schimmer, and Marc Studer have submitted a patent for the application of CO<sub>2</sub>/O<sub>2</sub> mixtures to mitigate negative effects of surgery and anesthesia.
